Rhonda Alkatib, MD
Allergy & Immunology · San Diego, CANPI 1417363086
Payments from drug & device makers
Across 586 payments — averaging $34.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$6K
- AstraZeneca$3K
- GSK$2K
- Sanofi$2K
- Regeneron Healthcare Solutions, Inc.$645
- Grifols USA, LLC$602
- plus $6K from 32 others
What the payments were for
- Consulting fees$4,62523%
- Travel & lodging$9265%
- Food & beverage$14,36272%
- Education$840%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 44 | $6,478 |
| AstraZeneca | 87 | $2,838 |
| GSK | 103 | $2,166 |
| Sanofi | 49 | $1,568 |
| Regeneron Healthcare Solutions, Inc. | 25 | $645 |
| Grifols USA, LLC | 19 | $602 |
| Amgen(2 entities) | 23 | $585 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $563 |
| Pfizer | 20 | $468 |
| Lilly USA, LLC | 10 | $371 |
| Incyte Corporation | 20 | $351 |
| Novartis | 20 | $338 |
| CSL Behring | 15 | $328 |
| Boehringer Ingelheim | 16 | $294 |
| Kaleo, Inc. | 15 | $272 |
| Blueprint Medicines Corporation | 7 | $228 |
| ARS Pharmaceuticals Operations, Inc. | 13 | $225 |
| LEO Pharma Inc. | 16 | $221 |
| Genentech, Inc. | 2 | $155 |
| Octapharma USA, Inc. | 4 | $150 |
| Alk-abello, Inc | 5 | $129 |
| Biocryst US Sales Co., LLC | 5 | $124 |
| Optinose US, Inc. | 7 | $121 |
| Greer Laboratories, Inc. | 4 | $112 |
| Shire North American Group Inc | 1 | $105 |
| Teva Pharmaceuticals USA, Inc. | 4 | $103 |
| Aimmune Therapeutics, Inc. | 4 | $87 |
| AbbVie | 3 | $64 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Ionis Pharmaceuticals, Inc. | 2 | $52 |
| Pharming Healthcare, Inc. | 2 | $50 |
| Phadia US Inc. | 3 | $49 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Cycle Pharmaceuticals Inc | 1 | $20 |
| Merck | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Arcutis Biotherapeutics, Inc. | 1 | $14 |
| Bio Products Laboratory USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,996 in reported general payments places this provider in the 80th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 44 | $193,842 |
| XolairOmalizumab | 43 | $111,400 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $95,327 |
| Dupixent PenDupilumab | 11 | $67,829 |
| FasenraBenralizumab | 12 | $66,545 |
| TezspireTezepelumab-Ekko | 12 | $50,028 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $28,796 |
| Spiriva RespimatTiotropium Bromide | 17 | $13,683 |
| Epinephrine | 32 | $6,980 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,871 |
| Azelastine Hcl | 91 | $2,340 |
| Pimecrolimus | 11 | $2,287 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $959 |
| Ventolin HfaAlbuterol Sulfate | 11 | $950 |
| Montelukast Sodium | 72 | $826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFasenra, Tezspire | $2,838 | $116,57324 claims |
| Genentech, Inc.Xolair | $155 | $111,40043 claims |
| CSL BehringHizentra | $328 | $95,32713 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $2,166 | $35,66750 claims |
| Boehringer IngelheimSpiriva Respimat | $294 | $13,68317 claims |
| Hikma Pharmaceuticals USAEpinephrine | $21 | $6,98032 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in San Diego
- Purvi MehraSan Diego$6.3M
- Bob GengSan Diego$6M
- Alexander GreinerSan Diego$4.8M
- Andrew WhiteSan Diego$1.2M
- Marc RiedlSan Diego$903K
- Bruce PrennerSan Diego$772K
- Katharine WoessnerSan Diego$581K
- Bruce ZurawSan Diego$232K
- Seema AcevesSan Diego$227K
- Stephanie LeonardSan Diego$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.